
A recent press release detailed the phase 3 findings that were presented at the virtual conference, which shows that bimekizumab was well-tolerated and efficacious in patients with moderate to severe plaque psoriasis.

A recent press release detailed the phase 3 findings that were presented at the virtual conference, which shows that bimekizumab was well-tolerated and efficacious in patients with moderate to severe plaque psoriasis.

Clinicians identified key strategies that could improve the challenge of treating lower back pain in emergency departments.

In research presented virtually at IDWeek 2021, investigators with the US Centers for Disease Control and Prevention conducted a review of nursing home antibiotic stewardship citation deficiencies in order to improve implementation.

Data from 5 trials presented at ID Week 2021 are promising for the investigational biotherapeutic.

Adult patients with moderate-to-severe atopic dermatitis reported incremental improvement of their condition in a new extension trial study presented at EADV.

Data show the 20-year cumulative incidence of AVR was 3.4% in mild AS, 20.2% in moderate AS, and 54.6% in severe AS.

Risky sexual behavior is the sole independent predictor of acute HDV.

Investigators reported that the vaccine prevented symptomatic and severe cases of COVID-19 in several populations including older patients.

Montefiore experts discuss the emphasis on education at their MFM-Cardiology care program.

Age, antibiotic use, and proton pump inhibitor use was associated with an increase in C difficile infections.

Maralixibat oral solution is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome.

Incarceration history and current opioid agonist treatment was associated with antibody testing.

The mean number of injections per year was 6.2 ± 1.4 injections following 1 year of treatment in 2007 - 2010 and 8.3 ± 2.0 injections in 2016 - 2017.

An obstetrician-gynecologist and a cardiologist discuss the inception of their joint cardiovascular care program for expecting mothers.

Investigators reported that the drug helped improve skin repigmentation in patients with vitiligo, but added that further studies were needed to fully explore its efficacy.

Healthcare provider knowledge on fecal microbiota transplantation as a treatment for inflammatory bowel disease is still lacking.

Additionally, investigators believe epidermal impairment in the skin of children with atopic dermatitis could contribute to the development of allergic sensitization.

Both proton pump inhibitors and histamine 2 receptor antagonists are commonly prescribed for stress ulcer prophylaxis in critically ill patients.

In patients with T2D without prior CVD, chronic kidney disease was the single risk factor associated with highest risk of MACE.

Analysis data show 3 times more risk of intensive care unit care in patients with venous thromboembolism compared to non-VTE patients (RR: 2.78).

Investigators believed the immunosuppressive qualities of these biologics posed no additional risk in contracting the COVID-19 virus, but added that additional research is warranted.

Michael Greenberg, MD, MPH, and Rick Nettles, MD, join Lungcast to discuss COVID-19 vaccine development, the 2021-22 flu season, RSV outbreaks, and more respiratory viruses.

Only 1 patient died due to HCV-related complications following liver transplantation.

Results show an increase in methamphetamine use, methamphetamine use disorder, and overdose mortality.

Investigators reported a significant difference in the expansion rate of the skin lesion area in patients with vitiligo in just 3 months of treatment.

Dr. Diaz said patience is important in understanding the challenges patients with ADHD face during the COVID-19 pandemic.

Acknowledging the potential medical harm from errors and bias, investigators believe clinical AI needs to be held to a higher standard.

The approval is based on 24- and 80-week findings showing significant benefit in LDL-C reduction with the subcutaneous injection drug.

Sotagliflozin reduced HbA1c by 0.42% and heart failure by 32% in comparison to placebo.

Dr. Castro considers it to be a fruitful and exciting time in the study of asthma-modifying therapy, with some biologic therapies achieving control in patients with severe asthma.